The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
January 10th 2025
Respiratory patterns and submental surface electromyography may be a reliable indicator of dysphagia among patients with myasthenia gravis.
PEF May Be Preferred Measure of Respiratory Strength for SMA Follow-Up
March 4th 2022With clear differences at baseline and subsequent declines seen in a linear pattern, the researchers suggested peak expiratory flow may be a suitable outcome measure for longitudinal assessment of respiratory muscle strength in these patients.
Read More
Dose Reduction May Lower Hair Loss Frequency, Allow for Longer Use of Isotretinoin for Acne
March 4th 2022Data from 22 studies were collected on reported hair loss with isotretinoin treatment, showing a hair loss frequency of 3.2% for patients receiving <0.5 mg/kg/day and a frequency of 5.7% for patients receiving ≥0.5 mg/kg/day.
Read More
Men, Smokers More Likely to Have Undiagnosed Asthma, According to Study
March 3rd 2022A recent study found that men, smokers, and older people are more likely to have asthma symptoms without a diagnosis of asthma, which can likely be attributed to other factors regarding their overall health.
Read More
Researchers Identify Potential Biomarkers for Combination Treatment Efficacy in NSCLC
March 3rd 2022A recent study demonstrates certain driver mutations in patients with non–small cell lung cancer (NSCLC) may shorten disease-free survival after combination neoadjuvant immunotherapy and chemotherapy.
Read More
Dr Soumya Chakravarty on Intertwined Pathophysiology of Psoriasis, Psoriatic Arthritis
March 2nd 2022Soumya Chakravarty, MD, PhD, FACP, FACR, strategic lead of the Rheumatology Therapeutic Area at Janssen, discussed the interlinked pathophysiology of psoriasis and psoriatic arthritis, and the involvement of inflammatory mediators for both conditions.
Watch
Report: Economic Burden of Rare Diseases Is 10 Times Higher Than Mass Market Diseases
March 2nd 2022The economic burden of rare diseases based on direct, indirect, and mortality-related costs is 10 times greater than the burden for mass market diseases, such as diabetes and cardiovascular disease, and this burden increases when no treatment is available.
Read More
Measures of Resistant Hypertension Linked to Worse Outcomes Among Black Adults
March 1st 2022A new study has investigated the influence of xanthine oxidase activity and mitochondrial DNA damage–associated molecular patterns on heart failure and cardiac remodeling among Black adults with resistant hypertension.
Read More
Shroff: Multiple Targets in Cholangiocarcinoma Make Biomarker Testing Essential
February 28th 2022Rachna Shroff, MD, associate dean of clinical and translational research and associate professor of medicine at the University of Arizona, offered a review of early-stage research in her talk, “The Hottest Targeted Therapies on the Horizon for Cholangiocarcinoma.”
Read More
Clinical, Scientific Updates at CCF 2022 Highlight Advances in Cholangiocarcinoma
February 27th 2022The co-chairs of the Cholangiocarcinoma Foundation 2022 meeting, Lipika Goyal, MD, MPhil, of Harvard and Massachusetts General Hospital, and Jesper B, Andersen, PhD, of the University of Copenhagen, Denmark, reviewed clinical and scientific developments.
Read More
Second Phase 3 Trial Shows Dupilumab Improves EoE in Patients 12 and Older
February 26th 2022During the annual meeting of the American Academy of Allergy, Asthma and Immunology, presenters said findings from a second phase 3 trial of dupilumab for eosinophilic esophagitis (EoE) continued to show the biologic improved symptoms in adults and adolescents.
Read More
With Natural Killer Cell Immunotherapy, Alloreactive Cell Dose May Be Predictive of Response
February 26th 2022Research has shown that adoptive immunotherapy using natural killer cells may be beneficial in leukemia treatment. The follow-up to a recent study found that the dose of alloreactive natural killer cells matters for treatment response.
Read More
How Employers Can Achieve High-Value, Cost-Effective Oncology Care Through Genomic Profiling
February 26th 2022A webinar by the National Cancer Treatment Alliance discussed current use and diagnostic/therapeutic benefits of comprehensive genomic profiling in oncology, as well as recommendations for employers and benefit consultants considering biomarker testing.
Read More
Understanding Complexity, Utilization Patterns of Patients at FQHCs
February 25th 2022On this episode of Managed Care Cast, Nadereh Pourat, PhD, MSPH, and Alex Sripipatana, PhD, MPH, discuss research on care complexity and utilization patters of patients at federally qualified health centers (FQHCs).
Listen